Cargando…
Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome
Metabolic syndrome is a constellation of risk factors including hypertension, dyslipidemia, insulin resistance, and obesity that promote the development of cardiovascular disease. Metabolic syndrome has been associated with changes in the secretion or metabolism of glucocorticoids, which have import...
Autores principales: | Schnackenberg, Christine G., Costell, Melissa H., Krosky, Daniel J., Cui, Jianqi, Wu, Charlene W., Hong, Victor S., Harpel, Mark R., Willette, Robert N., Yue, Tian-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613092/ https://www.ncbi.nlm.nih.gov/pubmed/23586038 http://dx.doi.org/10.1155/2013/427640 |
Ejemplares similares
-
11β-Hydroxysteroid Dehydrogenases and Hypertension in the Metabolic Syndrome
por: Bailey, Matthew A.
Publicado: (2017) -
Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases
por: Markey, Keira A, et al.
Publicado: (2016) -
Cortisol, Hypertension and Obesity: The Role of 11β-Hydroxysteroid Dehydrogenase
por: Stewart, Paul M
Publicado: (1998) -
11β-Hydroxysteroid Dehydrogenase 2 in Preeclampsia
por: Kosicka, Katarzyna, et al.
Publicado: (2016) -
Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2
por: Thompson, George R, et al.
Publicado: (2019)